3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
17
Urinary Bladder Neoplasms
10
Kidney Neoplasms
6
Pancreatic Neoplasms
4
Neoplasms
4
Head and Neck Neoplasms
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Melanoma
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Testicular Neoplasms
2
Stomach Neoplasms
2
Skin Neoplasms
2
Sarcoma
2
Muscle-invasive Bladder Cancer
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Liver Neoplasms
2
Laryngeal Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Central Nervous System Neoplasms
2
Carcinoma, Transitional Cell
2
Interventions
osimertinib
2
Trastuzumab
2
Magnetic Resonance Spectroscopy
2
Immunoglobulin G
2
Fulvestrant
2
ulixertinib
1
tucatinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
seribantumab
1
sapanisertib
1
relatlimab
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
ferumoxtran-10
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
cobimetinib
1
cemiplimab
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Surveys and Questionnaires
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
Drug Therapy
×
Genitourinary
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled